Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175498 | 0.77 | ABCC4 (0.34) | — | |
| SCHEMBL2875011 | 0.70 | TSHR (0.30) | TSHR | |
| SCHEMBL4563837 | 0.70 | MCL1 (0.32) | TSHR | |
| SCHEMBL235304 | 0.67 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL9661307 | 0.65 | ALOX15 (0.33) | ALDH1A1 | |
| SCHEMBL7591793 | 0.65 | ALDH1A1 (0.35) | ALDH1A1TSHRFGFR4 | |
| SCHEMBL17201496 | 0.65 | TSHR (0.31) | ALDH1A1TSHR | |
| SCHEMBL22988 | 0.64 | — | — | |
| SCHEMBL8064324 | 0.64 | TSHR (0.41) | TSHR | |
| SCHEMBL9328869 | 0.63 | ALDH1A1 (0.33) | ALDH1A1TSHRFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0273270-B1 | PROCESS FOR THE PREPARATION OF (+)-BIOTIN | LONZA AG (CH) | 1992-04-08 | — | — | EP | claimed |
| EP-0270076-B1 | IMIDAZOLE DERIVATIVES AND A PROCESS FOR THEIR PREPARATION | LONZA AG (CH) | 1991-10-09 | — | — | EP | claimed |
| EP-0299634-A2 | Silicone polymer termination | DOW CORNING CORPORATION (US) | 1989-01-18 | — | — | EP | claimed |
| US-4766192-A | MIXING POLYDIORGANOSILOXANE WITH PHOSPHORIC AND SILYLAMIDE COMPONENT | DOW CORNING CORPORATION (US) | 1988-08-23 | — | — | US | claimed |
| US-7825103-B2 | 5'-O-triisopropylsilyl-2'-cyano-2'-deoxy-1- beta -D-arabinofuranosylcytosine; antitumor agents | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20090118222-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1845102-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1185365-A1 | SURFACE-MODIFIED MIXED OXIDES CONTAINING PRECIOUS METAL AND TITANIUM, FOR THE SELECTIVE OXIDATION OF HYDROCARBONS | Bayer Aktiengesellschaft (DE) | 2002-03-13 | — | — | EP | disclosed |
| US-20010051754-A1 | PLURAL STAGE TOLUENE DISPROPORTIONATION PROCESS MINIMIZING ETHYLBENZENE | MOBIL OIL CORPORATION | 2001-12-13 | — | — | US | disclosed |
| WO-2001009067-A1 | PLURAL STAGE TOLUENE DISPROPORTIONATION PROCESS MINIMIZING ETHYLBENZENE PRODUCTION | MOBIL OIL CORPORATION (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000064582-A1 | SURFACE-MODIFIED MIXED OXIDES CONTAINING PRECIOUS METAL AND TITANIUM, FOR THE SELECTIVE OXIDATION OF HYDROCARBONS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-02 | — | — | WO | disclosed |
| EP-0375040-A2 | Process for the preparation of retro-inverso peptides and new intermediates thereof | SCLAVO S.p.A. (IT) | 1990-06-27 | — | — | EP | disclosed |
| US-4234721-A | Process for the preparation of the crystalline monohydrate of 7-[D-amino-(p-hydroxyphenyl]acetamido)-3-methyl-3-cephen-4-carboxylic acid | BRISTOL-MYERS COMPANY (US) | 1980-11-18 | — | — | US | disclosed |
| US-4171431-A | Nucleosides and process | THE UPJOHN COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
| US-4160863-A | ANTIBIOTIC | BRISTOL-MYERS COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4066657-A | ANTIBACTERIAL AGENTS FOR ANIMAL FEED SUPPLEMENTS | PFIZER INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4036846-A | ANTIBACTERIAL | PFIZER INC. (US) | 1977-07-19 | — | — | US | disclosed |
| US-4031077-A | Antibacterial 3-phosphono penams | PFIZER INC. (US) | 1977-06-21 | — | — | US | disclosed |
| US-3994939-A | BACTERICIDES | PFIZER INC. (US) | 1976-11-30 | — | — | US | disclosed |
| US-3943123-A | ANTIBIOTIC | KONINKLIJKE NEDERLANDSCHE GIST-EN SPIRITUSFABRIEK N.V. (NL) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118222-A1 | NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT | CDK10, SRSF9, SNRPD1 | ALDH1A1 3707/4885TSHR 2261/4885FGFR4 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.